UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2015
Commission File Number 001-36866
SUMMIT
THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton
Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F x FORM 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
YES ¨ NO
x
If Yes is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
On September 2, 2015, Summit Therapeutics plc (the Company) issued a press release announcing
the appointment of Ralf Rosskamp, M.D., as its Chief Medical Officer. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC |
|
|
By: |
|
/s/ Erik Ostrowski |
|
|
Erik Ostrowski |
|
|
Chief Financial Officer |
Date: September 3, 2015
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release dated September 2, 2015 announcing appointment of Ralf Rosskamp, M.D., as Chief Medical Officer |
Exhibit 99.1
Summit Therapeutics plc
(Summit or the Company)
SUMMIT
THERAPEUTICS APPOINTS RALF ROSSKAMP, MD, AS CHIEF MEDICAL OFFICER
Oxford, UK, 2 September 2015 Summit Therapeutics plc (AIM: SUMM,
NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), today announced the appointment of Dr Ralf Rosskamp as Chief Medical
Officer. Dr Rosskamp was most recently Vice President, Global Clinical Development, at NPS Pharmaceuticals, where he oversaw the development of several rare disease drug candidates from early clinical stage through to regulatory approval. Dr
Rosskamp will be based in the Companys US office in Cambridge, Massachusetts.
Dr Rosskamps 25 years of drug development and
regulatory expertise, especially his experience with rare and paediatric diseases, are a great fit with Summit and our clinical programmes said Glyn Edwards, Chief Executive Officer of Summit. He is joining at a
really exciting time as we initiate Phase 2 trials in our utrophin modulator programme for DMD and look forward to reporting data from our proof of concept Phase 2 trial of SMT19969 for CDI. We welcome him to the team.
Summits diverse programmes find common ground in their aim to truly advance the current state of care. In DMD, utrophin modulation has
potential as a disease-modifying therapy for all patients with this devastating disease, and in CDI, Summits novel antibiotic candidate could reduce the rate of disease recurrence, commented Dr
Rosskamp. I look forward to advancing both of these compounds as we seek to bring them to the patients in need.
About Ralf Rosskamp, MD
Dr Rosskamp brings to Summit
broad drug development and regulatory expertise from his career in the biotechnology industry. He has been responsible for numerous investigational new drug applications, the design and execution of clinical development programs, and new drug
applications across multiple therapeutic areas including rare diseases. Dr Rosskamp has been involved in the approval of a number of products including Amaryl®, Lantus®, Apidra®, Simcor®, and most recently the FDA authorisation of Natpara® for the treatment of a rare endocrine disease called hypoparathyroidism.
Prior to joining NPS
Pharmaceuticals, which was subsequently acquired by Shire Pharmaceuticals, he was Executive Vice President, R&D at rare disease specialist Ikaria. Dr Rosskamp has also served as Executive Vice President, R&D of Kos Pharmaceuticals (acquired
by Abbott Labs), Vice President, Global Therapeutic Area Endocrinology, Metabolism, Rheumatology and Bone at Aventis Pharmaceuticals and Head, Clinical Research Metabolism and Global Clinical Director, Recombinant Products at Hoechst AG. In
his academic career, Dr Rosskamp served as Associate Professor, Pediatric Endocrinology in the Department of Pediatrics at the University of Bonn. He received his MD in paediatrics from the University of Bonn.
About Summit Therapeutics
Summit is a biopharmaceutical
company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne
muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
|
|
|
Summit Therapeutics Glyn Edwards /
Richard Pye (UK office) Erik Ostrowski (US office) |
|
Tel: +44 (0)1235 443 951
+1 617 294 6607 |
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) Liam Murray / Tony Rawlinson |
|
Tel: +44 (0)20 7148 7900 |
|
|
N+1 Singer (Broker)
Aubrey Powell / Jen Boorer |
|
Tel: +44 (0)20 7496 3000 |
|
|
MacDougall Biomedical Communications (US
media contact) Michelle Avery |
|
Tel: +1 781 235 3060
mavery@macbiocom.com |
|
|
Peckwater PR (Financial public
relations, UK) Tarquin Edwards |
|
Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk |
Forward Looking Statements
Any statements in this press release about Summits future expectations, plans and prospects, including but not limited to, statements about the clinical
and preclinical development of Summits product candidates, the therapeutic potential of Summits product candidates, the timing of initiation, completion and availability of data from clinical trials and expectations regarding the
sufficiency of Summits cash balance to fund operating expenses and capital expenditures, and other statements containing the words anticipate, believe, continue, could, estimate,
expect, intend, may, plan, potential, predict, project, should, target, would, and similar expressions, constitute forward
looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials, availability and timing of data from on-going and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summits
foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the Risk Factors section of filings that Summit makes with the Securities and Exchange Commission including
Summits Annual Report on Form 20-F for the fiscal year ended January 31, 2015. Accordingly readers should not place undue reliance on forward looking statements or information. In addition, any forward looking statements included in this
press release represent Summits views only as of the date of this release and should not be relied upon as representing Summits views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking
statements included in this press release.
- END -
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024